EDAP to Accelerate Treatment Rates at Study Centers

***Please view using updated link below*** October 5, 2009 We are pleased to announce that WRAL-TV (CBS affiliate) in Raleigh, North Carolina recently aired a piece on EDAP's ongoing clinical trial of Ablatherm High-Intensity Focused Ultrasound (HIFU) as a robotized, non-invasive treatment in

Italian Study Shows Up to 90% Efficacy at 12 Months in Stage T2b and T3 High Risk Patients

LYON, France , Aug. 26, 2013 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by EDAP TMS SA (Nasdaq:EDAP), please note that the presentation time should be 10:50 am ET — 11:15 am ET , rather than 10:25 am ET — 10:50 am ET as originally stated.

Dr. Andrew Weil on Ablatherm-HIFU We are proud to announce that Dr. Andrew Weil, a well-known physician and author, recently spoke of the benefits associated with Ablatherm-HIFU minimally invasive, robotized technology. Please click on the below link to view Dr.

Center is First in Tennessee to Evaluate New HIFU System for Prostate Cancer

LYON, France, Mar 22, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today that the INSERM team and Emmanuel Blanc, the Company's Chief Technology Officer, have been nominated for the European Inventor Award 2010.

Comprehensive Data Supports Prostate Cancer Control Utilizing Ablatherm(R)-HIFU

EDAP Ablatherm-HIFU Presents at American Urology Association Accelerates US Study Enrollment LYON, France , May 23 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports the continuing advancement

EDAP Ablatherm-HIFU Strongly Highlighted in European Congresses LYON, France , June 18 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports continued and sustained marketing presence in various